TTY Biopharm Past Earnings Performance
Past criteria checks 2/6
TTY Biopharm has been growing earnings at an average annual rate of 6.7%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 7% per year. TTY Biopharm's return on equity is 16.6%, and it has net margins of 19.2%.
Key information
6.7%
Earnings growth rate
6.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 7.0% |
| Return on equity | 16.6% |
| Net Margin | 19.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly
Apr 02
Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?
Mar 15Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?
Feb 25TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Feb 07TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially
Jan 19What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Jan 10
TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet
Dec 15How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?
Nov 25Revenue & Expenses Breakdown
How TTY Biopharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5,826 | 1,120 | 1,739 | 327 |
| 30 Jun 24 | 5,726 | 1,124 | 1,659 | 351 |
| 31 Mar 24 | 5,613 | 1,171 | 1,574 | 330 |
| 31 Dec 23 | 5,506 | 1,129 | 1,599 | 310 |
| 30 Sep 23 | 5,394 | 1,168 | 1,543 | 293 |
| 30 Jun 23 | 5,287 | 1,130 | 1,546 | 312 |
| 31 Mar 23 | 5,191 | 1,106 | 1,515 | 345 |
| 31 Dec 22 | 5,062 | 1,094 | 1,440 | 353 |
| 30 Sep 22 | 4,997 | 1,193 | 1,396 | 350 |
| 30 Jun 22 | 4,731 | 1,109 | 1,360 | 323 |
| 31 Mar 22 | 4,609 | 856 | 1,340 | 295 |
| 31 Dec 21 | 4,536 | 832 | 1,338 | 288 |
| 30 Sep 21 | 4,270 | 751 | 1,330 | 267 |
| 30 Jun 21 | 4,235 | 720 | 1,382 | 251 |
| 31 Mar 21 | 4,092 | 874 | 1,365 | 253 |
| 31 Dec 20 | 4,222 | 924 | 1,388 | 262 |
| 30 Sep 20 | 4,130 | 693 | 1,405 | 274 |
| 30 Jun 20 | 4,255 | 787 | 1,369 | 295 |
| 31 Mar 20 | 4,445 | 860 | 1,402 | 300 |
| 31 Dec 19 | 4,466 | 900 | 1,375 | 299 |
| 30 Sep 19 | 4,447 | 1,236 | 1,305 | 320 |
| 30 Jun 19 | 4,204 | 1,263 | 1,264 | 324 |
| 31 Mar 19 | 4,110 | 1,499 | 1,253 | 358 |
| 31 Dec 18 | 4,036 | 1,461 | 1,242 | 361 |
| 30 Sep 18 | 4,102 | 1,696 | 1,225 | 332 |
| 30 Jun 18 | 4,240 | 1,631 | 1,210 | 331 |
| 31 Mar 18 | 4,173 | 1,379 | 1,161 | 294 |
| 31 Dec 17 | 4,079 | 1,345 | 1,116 | 296 |
| 30 Sep 17 | 3,874 | 1,088 | 1,097 | 322 |
| 30 Jun 17 | 3,765 | 1,023 | 1,079 | 321 |
| 31 Mar 17 | 3,795 | 1,134 | 1,063 | 340 |
| 31 Dec 16 | 3,761 | 1,193 | 1,038 | 342 |
| 30 Sep 16 | 3,733 | 1,536 | 1,055 | 354 |
| 30 Jun 16 | 3,612 | 1,565 | 1,035 | 337 |
| 31 Mar 16 | 3,389 | 1,393 | 1,048 | 317 |
| 31 Dec 15 | 3,195 | 1,211 | 1,053 | 340 |
| 30 Sep 15 | 3,058 | 1,133 | 1,060 | 328 |
| 30 Jun 15 | 2,929 | 986 | 1,080 | 348 |
| 31 Mar 15 | 2,969 | 829 | 1,132 | 370 |
| 31 Dec 14 | 2,980 | 780 | 1,191 | 369 |
| 30 Sep 14 | 2,976 | 196 | 1,234 | 394 |
| 30 Jun 14 | 2,995 | 94 | 1,312 | 400 |
| 31 Mar 14 | 2,957 | 124 | 1,315 | 390 |
| 31 Dec 13 | 3,110 | 587 | 1,325 | 384 |
Quality Earnings: 4105 has high quality earnings.
Growing Profit Margin: 4105's current net profit margins (19.2%) are lower than last year (21.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4105's earnings have grown by 6.7% per year over the past 5 years.
Accelerating Growth: 4105's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4105 had negative earnings growth (-4.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (11.9%).
Return on Equity
High ROE: 4105's Return on Equity (16.6%) is considered low.